| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10963725 | Vaccine | 2015 | 9 Pages |
Abstract
All TDV doses and dosing schedules were well tolerated and immunogenic in healthy flavivirus-naive adults (ClinicalTrials.gov NCT01511250).
Keywords
PBSTDVsafety setMultiple administrationFASqRT-PCRSAEGMTDenDENVPpsDose titrationSafetyImmunogenicityfull analysis setper protocol setDoseadverse eventSerious adverse eventPhosphate-buffered salinegeometric mean titersplaque forming unitsTetravalent dengue vaccineQuantitative reverse-transcriptase polymerase chain reactionpfuClinical trial
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Richard Rupp, Gary Joseph Luckasen, Judith Lee Kirstein, Jorge E. Osorio, Joseph D. Santangelo, Marsha Raanan, Mary Kathryn Smith, Derek Wallace, Gilad S. Gordon, Dan T. Stinchcomb,